rTMS With and Without Text4Support for the Treatment of Resistant Depression.

Launched by UNIVERSITY OF ALBERTA · Oct 5, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating how effective a treatment called rTMS (repetitive Transcranial Magnetic Stimulation) is for people with depression that hasn’t improved with standard medications. The study will look at two groups: one group will receive rTMS along with a supportive text messaging program called Text4Support, while the other group will receive rTMS treatment alone. Researchers hope to find out if adding text support can make the treatment more effective.

To join the study, participants must be at least 18 years old, have been diagnosed with major depressive disorder, and have tried two or more antidepressants without success. Participants will go through six weeks of treatment, followed by check-ins at one, three, and six months to see how they are doing. This study is open to anyone, regardless of gender, and takes place at four centers in Canada, including Edmonton and Nova Scotia. If you or a loved one are interested in participating, it's important to have a smartphone to receive text messages and be willing to provide consent to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • aged 18 and above and diagnosed with MDD based upon the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and who have at least failed two or more standard antidepressant treatments during the current episode. Participants may be on psychotropic medications including antidepressants, antipsychotics, benzodiazepines, and anticonvulsants. They must have a good understanding of the English language. Must have access to a smartphone and be able to receive and read text messages. Must be willing to provide written informed consent upon acceptance into the study.
• Exclusion Criteria:
• • Patients below the age of 18.
• • Having diagnosis such as the following conditions (current unless otherwise stated): A neurological disorder, including a history of seizures, having primary or secondary tumors in the central nervous system, cerebrovascular disease, stroke, cerebral aneurysm, movement disorder,
• • Having a current psychotic disorder such as substance-induced psychosis, psychotic disorder due to a medical condition, or MDD with psychotic features at the time of screening
• • Having a current personality disorder that may hinder the patient's participation in this research or may have the potential of affecting cognition and ability to fully participate in the study.
• • Having a learning disability as per identified through medical history or by the investigator during the assessment process.
• • Participants involved in any drug or device clinical trial within the last six weeks before the screening visit and/or involvement in another clinical trial for the duration of this study.
• • Pregnant and breastfeeding women.
• • Identification and/or the sudden appearance of any condition or instance from the mentioned above and based on the expertise of the investigators that have the potential to hinder the progress and completion and/or become a confounding factor on the outcome assessments.